US-based Bioheart has unveiled plans to set up two centres of excellence in the region to provide its cell therapy procedures to patients of congestive heart failure and peripheral arterial disease. The company has commenced work in Jordan on its Regen trial, a phase I clinical trial to test genetically modified MyoCell in patients suffering from congestive heart failure. The first patient is expected to receive treatment in July. The firm also has plans for establishing a cell manufacturing facility in Jordan as well.